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Abstract 
MicroRNAs (miRNAs) are important gene regulators, which are often deregulated in cancers. In this study, we 
analyzed the microRNAs profiles of 78 matched cancer/noncancerous liver tissues from HCC patients and 10 
normal liver tissues and found that 69 miRNAs were differentially expressed between hepatocellular carcinoma 
(HCC) and corresponding noncancerous liver tissues (N).Then the expressions of  8 differentially expressed 
miRNAs were validated by real time RT PCR.The set of differentially expressed miRNAs could distinctly 
classify HCC,N and normal liver tissues (NL).Moreover, some of these differentially expressed miRNAs were 
related to the Medical factors of HCC patients. The paper further examines the feasibility of a subfamily of 
Weibull model. This feasibility is judged based on Bayes information criterion by comparing the Weibull model 
with its subfamily. Finally we conclude our Mathematical results that the figures 1- A,figure 1-B, figure 1-C is 
well fitted in the Weibull survival model and  the maximum value of SK-Hep-1, Hep G2 and SMMC 7721 at 
the time has been obtained .This will be helpful for the medical professional. 
 Keywords: Hepatocellular Carcinoma, microRNA, Weibull distribution. 
Mathematical subject classification: 60 Gxx, 62Hxx, 62Pxx. 
 
I.  Applications 
MicroRNAs  (miRNAs)  are  defined  as  a 
class of naturally occurring, 19-25 nt long noncoding 
single-stranded RNA species, which are cleaved from 
70-80  nt  microRNA  precursor  transcripts  [1]. 
MiRNAs can regulate gene expression either at the 
transcriptional or at the translational levels, based on 
specific  binding  to  the  complementary  sequence  in 
coding  or  noncoding  region  of  miRNA  transcripts 
[2]. Recent findings, based on microarray analysis of 
global miRNA expression profiles in cancer tissues 
versus  normal  counterparts,  have  revealed  that 
miRNA profiles could discriminate malignancies of 
breast,  lung,  pancreas,  liver  and  leukemia  from 
normal  counterpart  [5,  17,  20,  28].  More  notably, 
some  specific  miRNAs  have  been  reported  with 
predictive significance for prognosis of lung cancer 
and lymphocytic leukemia [4, 24, 29], thus indicating 
that  miRNAs  may  play  crucial  roles  in  human 
oncogenesis. Hepatocellular carcinoma (HCC) is one 
of the most prevalent and lethal cancers in East Asia 
and  South  Africa.Murakami  et  al.  reported  that 
miRNAs could discriminate HCC from noncancerous 
liver tissues (N) in 25 paired samples [20]. Recently, 
Jiang et al [12] and Budhu et al [3]. In this study, we 
described miRNA  global  microarray analysis of 78 
HCC and corresponding noncancerous liver tissues as 
well  as  10  normal  liver  tissues  (NL).The  miRNA 
expression  profiles  could  discriminate  HCC  from 
both  noncancerous  and  normal  liver  tissues,  and  a 
single  miRNA  miR-125b  can  provide  predictive 
significance for prognosis of HCC patients. 
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Figure: 1 Hsa-miR-125b could suppress the growth of liver cancer cells.SK-Heb-1 (a),Heb G2 (b) and SMMC 
7721 (c) cells were transfected with pQXIN vector (control).Cells were seeded into triplicate wells of 24 well 
culture plates on day 0.Adherent cells were counted on 24,48 and 72 hr after transfection.Mean values are 
plotted as shown; error bars represent the standard deviation of mean values from 3 independent experiments. 
 
II.  Mathematical Model 
The  p.d.f  of  two-parameter  Weibull 
distribution can be written as 
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where α is the scale parameter and β determines the 
shape of the distribution. The corresponding survival 
function can be given by 
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The  Weibull  distribution  encompasses 
monotonically  increasing  (for  β>1),  decreasing  (for 
β<1), and constant (for β=1) failure rate and, as such, 
the model has been successfully used to describe both 
initial failures as well as the failures due to remission 
or aging [16]. One of the biggest advantages with the 
Weibull  model  is  the  availability  of  closed  form 
survival function, which makes the inferences related 
to the model quite easy although the non-availability 
of  sufficient  statistics  poses  some  problem  in 
comparison to those situations where the existence of 
the  same  is  guaranteed.  The  Weibull  model  is 
perhaps  the  richest  one  as  far  as  the  inferential 
developments  are  concerned  both  with  regard  to 
classical and Bayesian paradigms.[16] is an important 
text  which  systematically  describes  the  classical 
developments based on the model both in the context 
of engineering and medical applications. A few other 
important  references  include  [14],  [18]  and,  more G.Ramya Arockiamary et al Int. Journal of Engineering Research and Applications    www.ijera.com 
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recently,  in  [23].The  other  important  references 
include [8],[10]. The distribution is, in general, not 
too  straightforward  to  deal  with.  The  classical 
developments  on  the  model  mostly  relied  on  large 
sample  approximations  or  empirical  results.  The 
problem  with  the  Bayesian  inferences  lies  in  the 
involvement  of  integrals  in  the  posterior  based 
inferences,  which  are  difficult  to  solve  analytically 
and,  as  such,  require  specialized  techniques  of 
Bayesian  computation  [6,  26].This  last  reference 
advocated  the  use  of  sample  based  approaches  in 
Bayesian  computation  because  of  their  several 
inherent  advantages.  A  few  such  advantages  may 
include the straightforwardness of the procedures to 
deal  with  censored  data  problems  and  routine 
inferential development for some nonlinear functions 
of  the  model  parameters.  The  Weibull  distribution 
becomes straightforward if one is confronted with a 
situation where shape parameter β can be taken to be 
unity.  The  resulting  distribution  becomes  one-
parameter  exponential  and  inferential  developments 
based on it are routine. This is equivalent to say that 
an experimenter tests β against unity  for the  given 
data  set  and  goes  for  the  exponential  model  if  the 
hypothesis  is  accepted.  Such  problems  have  been 
considered  earlier  by  a  number  of  authors  in  both 
classical  and  Bayesian  paradigms.  The  most 
frequently  used  classical  tool  for  testing  β  against 
unity is based for the Weibull model. For Bayesians, 
the  obvious  techniques  can  be  based  on  the 
evaluation  of  Bayes  factor  which  is  a  bit  difficult 
when the priors are non-informative and the data are 
compounded  with  censoring  mechanism  [25].  The 
problem of testing β = 1 can also be visualized as that 
of  model. No doubt, this  measure is comparatively 
easy and provides answers parallel to that based on 
Bayes factor.  A model comparison is justified among 
the  compatible  models  only  where  compatibility  is 
referred  to  mean  that  all  the  models  under 
considerations do provide an adequate representation 
to  the  given  data.  Therefore,  we  first  propose  a 
compatibility  study  of  the  exponential  and  Weibull 
models and then provide a model comparison study 
to pick up an appropriate on Bayesian version of chi-
square  discrepancy  measure.The  posterior 
corresponding the exponential distribution when β = 
1 has also been commented briefly. Results based on 
exponential  modeling  assumption  have  also  been 
given for completeness.  
 
III.  Mathematical Results 
 
Probability density function for SK-Hep – 1 corresponding to figure  1-A 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
hep-1-miR-125b hep-1-PQ hep-1
f
(
x
)
Time
Figure-1-A
Series3
Series2
Series1G.Ramya Arockiamary et al Int. Journal of Engineering Research and Applications    www.ijera.com 
ISSN : 2248-9622, Vol. 4, Issue 5( Version 2), May 2014, pp.03-08 
 
 
www.ijera.com                                                                                                                                 6 | P a g e  
 
 
Probability density function for Hep G2 corresponding to figure 1-B 
 
 
Probability density function for SMMC 7721 corresponding to figure 1-C 
 
IV. Discussion 
In this study, 78 pairs of HCC and matched 
noncancerous  tissues  and  10  normal  liver  tissues 
were used for miRNAs microarray assays. From our 
data,  the  differential  expressed  miRNAs  could 
distinctly  discriminate  HCC  from  their  matched 
noncancerous  liver  and  10  normal  liver  tissues. 
Additionally  we  have  to  mention  that  the  miRNA 
profile  we  found  to  be  diagnostic  for  HCC  was 
partially consistent with those reported by Murakami 
[20].Among  their  7  top  nature  miRNAs,5  (mir-
18,mir-224,mir-199a,mir-199a
*,mir-195)  were  also 
among  miRNAs  we  found  to  be  differentially 
expressed  in  HCC  versus  noncancerous  liver.  The 
discrepancy  in  other  miRNAs  may  be  attributed  to 
the different miRNA probes we used or the different 
etiological  factors  involved  in  HCC  comprised 
Aflatoxin  and  hepatitis  B  virus  infection,  which 
accounted for more than 84% of HCC cases. Also the 
difference  in  genetic  background  between  these 
ethnic groups remained unclear.Therefore, the partial 
difference in miRNA species involved in HCC from 
2 countries was not expected. Besides, expression of 
hsa-miR-122a was down regulated in hepatocellular 
carcinoma in our study, as reported by Gramantieri et 
al  [9].and  Kutay  et  al  [15].    Among  the  HCC 
discriminative  signature  miRNAs  in  our  studies, 
some  miRNAs  may  be  commonly  deregulated  in 
other cancers derived from different tissues reported 
previously. For example,hsa-miR-221 and hsa-miR-
222  were  found  deregulated  in  thyroid  papillary 
carcinomas;has-miR-181a  in  glioblastoma;hsa-miR-
15b,hsa-miR-107  and  Let-7  in  acute  promyelocytic 
leukemia  [7].  Taken  together,  miRNA  species 
deregulated  commonly  in  diverse  type  of  cancers 
might  possibly  play  crucial  roles  in  human 
carcinogenesis  and  cancer  progression.  Although 
miRNA profile did reveal very prospective features 
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in cancer, the functions and real targets of miRNAs 
were  largely  unknown.Recently;  Slack’s  group  has 
proved  that  the  Let-7  family  could  down  regulate 
RAS in C.elegans as well as in human cells [13]. In 
addition,  the  PTEN  gene  was  targeted  by  hsa-mir-
21[24],  cyclin  G1  by  hsa-mir-222.  The  predicted 
targets  of  the  majority  of  microRNAs  based  on 
sequence homology remained to be comprehensively 
validated by in  vitro and in  vivo experiments. The 
molecular  events  underlying  the  altered  miRNA 
profiles  in  HCC  need  to  be  further  extensively 
investigated  by  using  conventional  gene  expression 
microarray  and  proteomic  analysis.The  most 
important finding in our study is the discovery of the 
specific  miRNA  related  to  prognosis  of  HCC 
patients, hsa-miR-125b.The expression level of hsa-
miR-125b in HCC tissues is generally downregulated 
as compared with that of noncancerous liver tissues. 
On the basis of the survival analysis, we found that 
HCC patients with high expression of hsa-miR-125b 
had good prognosis, while those with low expression 
gave  poor  clinical  outcomes.  By  the  reports,  miR-
125b were commonly deregulated in cancers derived 
from  different  histotypes,  such  as  prostate  cancer, 
breast cancer and thyroid anaplastic carcinomas [11, 
21, 27]. Furthermore, depletion of miR-125b had a 
profound  effect  on  the  proliferation  of  adult 
differentiated  cancer  cells.Overexpression  of  miR-
125b could suppress and invasion phosphorylation of 
ERK1/2 and Akt and reduce migration and invasion 
capacities of human breast cancer cell [22]. Besides, 
miR-125b played an important role in innate immune 
response. So these reports suggested the importance 
of  miR-125b  in  cancers.But,to  the  best  of  our 
knowledge, there is no report so far on the function of 
hsa-miR-125b in HCC.Our studies showed that miR-
125b  obviously  suppressed  growth  of  hepatoma 
cells.Next,we  analyzed  the  putative  target  of  miR-
125b  and  found  several  serine/theronine  protein 
kinase and related genes were involved, such as ras-
related  protein  Rab-13(RAB13),serine/threonine-
protein  kinase  13(AURKC),tyrosine-proteinkinase 
receptor Tie-1 precursor(TIE1) and phosphoinositide 
3-kinase regulatory subunit 5(PIK3R5).These results 
suggested that mir-125b may repress the cell growth 
by inhibiting the protein kinases.Akt was reported to 
be  the  most  important  downstream  signaling 
mediator of phosphoinositide 3-kinase and crucially 
controlling  cell  survival  and  proliferation.  So  we 
further investigated the possible role of miR-125b on 
phosporylation of Akt.The results showed that miR-
125b could obviously suppress the phosporylation of 
Akt.Summarizing these results, this study implicated 
that  miR-125b  might  suppress  cancer  cell 
proliferation through inactivating Akt. 
 
V.  Conclusion 
miRNA signature was identified as a HCC 
diagnostic discriminator from both noncancerous and 
normal liver tissues. Most importantly, this is the first 
report  to  identify  single  miRNA  correlated  to  the 
HCC  prognosis.  that  is  hsa-miR-125b  as  a  HCC 
survival  predictor,the  mir-125  inhibits  cell  growth 
and  phosporylation  of  Akt  in  hepatoma  cells. 
Because a small set of miRNA species could reveal 
crucial  Medical  information,  these  tests  could  be 
readily  adapted  to  small  scale  microchips  or 
nanomere-based  assay  feasible  for  Medical 
application.. Finally  we conclude our Mathematical 
results that the figures 1- A, figure 1-B, figure 1-C is 
well  fitted  in  the  Weibull  survival  model  and    the 
maximum value of SK-Hep-1, Hep G2 and SMMC 
7721  at  the  time  has  been  obtained  .This  will  be 
helpful for the medical professional. 
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